Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS SC Actinic Keratosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy 26218

    ACTINIC KERATOSIS - SCORE

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - South Carolina Policy 26218 alerts

    Get alerted when Policy 26218 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy coverage for diclofenac sodium gel 3% used to treat actinic keratosis under the South Carolina Bronze 6T formulary. Coverage requires a trial of either topical fluorouracil or topical imiquimod.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy 26218
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionDocument a trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3% is covered.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Products affected
    2Required alternative topical therapies
    1Required generic trial before Rytary
    1Required generic trial before Zonisade
    Approved

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prior Zonisade continuation

    Coverage Criteria

    Diclofenac Sodium Gel 3% Step Therapy

    Covered when the member has completed a trial of either alternative topical therapy:

    ONE of

    • Trial of topical fluorouracil
    • Trial of topical imiquimod

    Rytary Initial Therapy

    Covered when the following requirement is met:

    Trial of one generic carbidopa/levodopa containing formulation

    Zonisade Initial and Continuation Therapy

    For a new start, covered when the following requirement is met:

    Trial of generic zonisamide capsule

    Step applies to new starts only. Approve for continuation of prior therapy.

    Documentation and Provider Actions

    Step Therapy

    Alternative Topical Therapy Required

    Before coverage of diclofenac sodium gel 3%, document a trial of an alternative topical therapy: either topical fluorouracil or topical imiquimod.

    • Required trial: topical fluorouracil or topical imiquimod.
    • Coverage may be denied when the required alternative topical therapy trial is not documented.
    Step Therapy

    Generic Carbidopa/Levodopa Trial Required

    Rytary requires documentation of a trial of one generic carbidopa/levodopa-containing formulation before coverage is approved.

    • Document completion of a trial with one generic carbidopa/levodopa-containing formulation.
    • Coverage may be denied when the required generic prerequisite trial has not occurred or is not documented.
    Step Therapy

    Initial Therapy Criteria

    Initial Therapy Requirement

    Covered when the following requirement is met:

    ONE of

    • Trial of topical fluorouracil
    • Trial of topical imiquimod

    Rytary Initial Therapy

    Covered when the following requirement is met:

    Trial of one generic carbidopa/levodopa containing formulation

    Zonisade Initial Therapy

    For a new start, covered when the following requirement is met:

    Continuation Therapy Criteria

    Zonisade Continuation Therapy

    Continuation is approved when the following criterion is met:

    Member is continuing prior therapy with Zonisade

    The step requirement applies to new starts only.

    Step-Therapy Requirements

    StepRequirement
    1Trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3% is covered.
    StepRequirement
    1Trial of one generic carbidopa/levodopa-containing formulation before Rytary.
    StepRequirement
    1Trial of generic zonisamide capsule before a new Zonisade start; continuation of prior Zonisade therapy is approved.
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy 26218
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionDocument a trial of either topical fluorouracil or topical imiquimod before diclofenac sodium gel 3% is covered.
    SourceLink
    On This Page
    Coverage CriteriaDocumentation and Provider ActionsInitial Therapy CriteriaContinuation Therapy CriteriaStep-Therapy Requirements

    Generic Zonisamide Trial Required for New Starts

    For new starts, Zonisade requires a trial of generic zonisamide capsules. Approve continuation when the member is already receiving prior therapy.

    • New-start requirement: document a trial of generic zonisamide capsule.
    • Continuation exception: approve for continuation of prior therapy.
    • Coverage may be denied for a new Zonisade start without the required generic zonisamide trial.
    Trial of generic zonisamide capsule

    Step applies to new starts only.